Get comprehensive coverage of Pandemic, including latest updates, analysis, insights, and expert commentary.
India has seen a fresh rise in Covid-19 infections with active cases crossing the 7,000 mark as of June 12, 2025. The country now has...
So far, the country's financial capital has recorded 7,68,610 cases of the virus.
The Union government has set aside an outlay of Rs 35000 crore for the procurement of the COVID-19 vaccine.
Andaman and Nicobar Islands becomes the first ST/UT to achieve the target of 100% double dose COVID-19 vaccination by only using the Covishield vaccine.
Serum Institute of India gets license to produce over two billion doses of the vaccine Covovax.
It is projected that if the current trends continue then the United Kingdom will exceed 1 million cases by the end of this month.
Nine people have tested positive for the omicron variant in Jaipur taking the total national tally to 21.
Total cases of Omicron variant in India reaches 12 after seven 7 more people tested positive in Maharashtra.
50% of the country’s population, that is eligible for vaccination is now fully vaccinated.
The fourth case of the Omicron variant has been confirmed in India
Two people in Karnataka have been diagnosed with the Omicron form for the first time in India. One was a South African citizen who had already left the country. In the last 24 hours, India recorded 9,765 new Covid-19 cases and 477 deaths.
In the Asia-Pacific region, Hong Kong and Japan said that they will increase travel restrictions, while Australia was ready for additional Omicron cases after at least two people visited multiple areas in the country's largest city while likely infected.
The WHO's Technical Advisory Group on Virus Evolution assembled on Friday and classified B.1.1.529 as a variant of concern and identified it as Omicron.
The EMA green light for the COVID-19 vaccine produced by Pfizer and German company BioNTech needs to be rubber-stamped by the EU’s executive branch, the European Commission, before health officials in member states begin offering shots.
Earlier this month, Pfizer said its pill curtailed the hazard of hospitalisation and mortality by almost 90% in people with mild to moderate COVID-19 viruses. Independent specialists suggested pausing the company’s study based on its likely results.